Anti-CD276 Antibody [C10-A1]

EM1709-85

Product Type:	Mouse monoclonal IgG1, primary antibodies
Species reactivity:	Human
Applications:	WB, IHC-P, FC
Molecular Wt:	57 kDa
Clone number:	C10-A1

Description: T cell activation and immune function are regulated by the innate immune system through positive and negative costimulatory molecules. One such molecule, B7-H3 (B7-homolog 3, also designated B7RP-2) belongs to the B7 Immunoglobulin superfamily. Soluble B7-H3 binds a putative receptor on activated T-cells that is distinct from CD28, CTLA-4, ICOS and PD-1. Widely expressed on nonlymphoid tissues, B7-H3 costimulates proliferation of both CD4+ and CD8+ T cells. The ability of B7-H3 to stimulate Th1 and cytotoxic-T cell responses suggest that it may have antitumor activity. B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, implicating B7-H3 as a potential therapeutic tool.

Immunogen: Recombinant protein

Positive control: CD276-hIgGFc transfected HEK293 cell lysate, human cervical cancer tissue, human ovarian cancer tissue, PC-3.

Subcellular location: Membrane.

Database links: SwissProt: Q5ZPR3 Human

Recommended Dilutions:

WB	1:500-1:2,000
IHC-P	1:200-1:1,000
FC	1:200-1:400

Storage Buffer: Purified antibody in PBS with 0.05% sodium azide.

Storage Instruction: 4℃; -20℃ for long term storage.

Purity: Protein A affinity purified.

Images



Fig1: Western blot analysis of CD276 on HEK293 (1) and CD276-hIgGFc transfected HEK293 (2) cell lysate using anti-CD276 antibody at 1/1,000 dilution.



Fig2: Immunohistochemical analysis of paraffin-embedded human cervical cancer tissue using anti-CD276 antibody. Counter stained with hematoxylin.



Fig3: Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue using anti-CD276 antibody. Counter stained with hematoxylin.



Fig4: Flow cytometric analysis of PC-3 cells with CD276 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; purple).

Background References

1. Seaman S et al. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell 31:501-515.e8 (2017).
2. Wilson KE et al. Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent. Theranostics 7:1463-1476 (2017).